Evercore ISI analyst Gavin Clark-Gartner initiated coverage of Jasper Therapeutics (JSPR) with an Outperform rating and $65 price target. Evercore ISI believes that Jasper’s briquilimab will have a roughly similar profile vs. Celldex’s (CLDX) barzovolimab, and potentially better dosing regimen, and will continue to close the valuation gap vs. Celldex, the analyst tells investors in a research note. In addition, Jasper is roughly 1-2 years behind Celldex and can use prior learnings to derisk the development path ahead, Evercore says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Jasper Therapeutics initiated with an Outperform at RBC Capital
- Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
- Cantor Fitzgerald biotech analysts to hold analyst/industry conference call
- Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria